Pfizer Inc (PFE) 29.86 $PFE
Most active New York Stock Exchange-traded stocks
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Acura Pharma Ends Agreement with Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:35PM CDT
Acura Pharmaceuticals entered into a letter agreement with Pfizer in connection with its license agreement for Oxecta.
Pfizer Set to Possibly Rebound After Yesterday's Selloff of 2.45%
Comtex SmarTrend(R) - Fri Apr 11, 3:47PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $29.83 to a high of $30.50. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $30.51 on volume of 40.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Pfizer to Potentially Rebound after Yesterday's 2.45% Sell Off
Comtex SmarTrend(R) - Fri Apr 11, 3:46PM CDT
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $29.83 to a high of $30.50. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $30.51 on volume of 40.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon?
at The Street - Fri Apr 11, 2:07PM CDT
Someone at Novartis screwed up today by sending out a mass email announcing the FDA approval of a new lung cancer drug ceritinib. Brand name: Zykadia. The only problem is FDA hasn't announced the approval of Zykadia yet.
Can This Drug Be a Game Changer for Eli Lilly?
George Budwell, The Motley Fool - Motley Fool - Fri Apr 11, 1:30PM CDT
Many large pharmas in the midst of the so-called "patent cliff" have chosen to turn to their development pipelines for new drugs, instead of playing the merger and acquisition game. This isn't entirely surprising given that valuations for many...
Midday Glance: Pharmaceuticals companies
AP - Fri Apr 11, 12:51PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Pfizer, Visa Weigh on the Dow Even as Banks Grab All the Attention
Dan Caplinger, The Motley Fool - Motley Fool - Fri Apr 11, 11:30AM CDT
It's natural for investors tracking the Dow Jones Industrials to focus on the huge impact that its banking components are having on the average today. With the Dow down 78 points as of 12:30 p.m. EDT, the index's two big investment banks are among...
Dow 30 Stock Roundup: Pfizer Drug Trial Dents, P&G Ups Dividend - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Apr 11, 10:06AM CDT
The Dow experienced an extremely volatile week due to the erratic behavior of momentum stocks.
Watch for Shares of Pfizer (PFE) to Approach Support at $29.93
Comtex SmarTrend(R) - Fri Apr 11, 9:48AM CDT
Pfizer (NYSE FE) has opened bearishly below the pivot of $30.85 today and has reached the first level of support at $30.27. Investors may be interested in a cross of the next downside pivot targets of $29.93 and $29.01.
GCC Select Cardiovascular Drugs Market 2012-16 - Analysis of the $7.6 Billion Industry
M2 - Fri Apr 11, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9g8257/market_for_select) has announced the addition of the "GCC Select Cardiovascular Drugs Market 2012-16 - Analysis of the $7.6 Billion Industry" report to their offering. This report focuses on the market for select cardiovascular drugs in the GCC region. Various market drivers in terms of changing lifestyle and rising disease incidence among the population has led to higher consumption of cardiovascular drugs in the region. Sensing the latent market opportunity, global pharma majors such as Novartis, Abbott, AstraZeneca have set up operations in the GCC region through local joint venture and distribution. The $7.6 bn Pharmaceutical industry in the GCC region is poised for major growth in the coming years. Increase in the international crude oil prices and exports of crude and petro products have transformed the GCC economy. The local governments are increasingly focusing on improving the health and living standards of the population. Contraints in local manufacturing capacity and thriving counterfeit drugs market pose a major challenge but improved regulatory mechanism, increase in private sector participation coupled with rising private and public sector outlay and spend on healthcare presents a promising future for the industry. In addition to market forecast upto 2016, the report also provides interesting insights into key molecules used, top brands, drug prices, procurement process among government and retail institutions. The report will serve as a effective guide for the drug companies, distributors, hospitals and other stakeholders who wish to enter the GCC healthcare market. The report also has profiles of companies and distributors in the GCC region. Key Topics Covered: 1. Methodology 2. Report Coverage 3. Glossary of terms 4. Executive summary 5. Healthcare sector in GCC 6. Pharmaceutical market in GCC 7. Cardiovascular market for select drugs in GCC 8. Profiles of key domestic pharmaceutical manufacturers 9. Annexure - Drugs price details by country - 2012 Companies Mentioned: - AstraZeneca - Global Pharma - Jamjoom Pharma - Julphar - Gulf Pharmaceutical Industries - Kuwait Saudi Pharmaceutical Industries - Merck & Co., Inc - National Pharmaceutical Industries Co - Neo Pharma - Novartis International AG - Oman Pharmaceutical Products Co. L.L.C - Pfizer, Inc - Sanofi S.A. - Saudi Pharmaceutical Industries & Medical Appliances Corporation - Tabuk Pharmaceuticals Manufacturing Company For more information visit http://www.researchandmarkets.com/research/9g...for_select
Priority Reviews, Preliminary Earnings Releases, Clinical Trials Results, and Launch of Website - Analyst Notes on Gilead, Pfizer, Intuitive Surgical, Alkermes and Quest
PR Newswire - Fri Apr 11, 9:14AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Intuitive Surgical, Inc. (NASDAQ: ISRG), Alkermes plc (NASDAQ: ALKS) and Quest Diagnostics Inc. (NYSE: DGX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/989-100free.
Pfizer's Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts
Business Wire - Fri Apr 11, 8:00AM CDT
Ian C. Read, chairman and CEO of Pfizer, Inc, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association's annual meeting. Also elected were Kenneth C. Frazier, chairman, president and CEO of Merck & Co, Inc., as chairman-elect of the PhRMA Board of Directors, and George A. Scangos, Ph.D., CEO of Biogen Idec, as Board treasurer.
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
2 Biotech Stocks to Watch: Merrimack Pharmaceuticals and Sunesis Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Apr 10, 5:30PM CDT
Although 2014 has gotten off to a rocky start for biotechs, a fair number of companies have exploded higher after reporting positive clinical trial data. For example, Endocyte doubled in a day after unveiling positive data for its experimental...
Nektar Presents Pipeline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:10PM CDT
Nektar presented preclinical data on NKTR-102 and NKTR-214 at the AACR.
Most active New York Stock Exchange-traded stocks
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Acura Pharma Ends Agreement with Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:35PM CDT
Acura Pharmaceuticals entered into a letter agreement with Pfizer in connection with its license agreement for Oxecta.
Pfizer Set to Possibly Rebound After Yesterday's Selloff of 2.45%
Comtex SmarTrend(R) - Fri Apr 11, 3:47PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $29.83 to a high of $30.50. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $30.51 on volume of 40.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. Look for Shares of Pfizer to Potentially Rebound after Yesterday's 2.45% Sell Off
Comtex SmarTrend(R) - Fri Apr 11, 3:46PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $29.83 to a high of $30.50. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $30.51 on volume of 40.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon?
at The Street - Fri Apr 11, 2:07PM CDT
Someone at Novartis screwed up today by sending out a mass email announcing the FDA approval of a new lung cancer drug ceritinib. Brand name: Zykadia. The only problem is FDA hasn't announced the approval of Zykadia yet.
Can This Drug Be a Game Changer for Eli Lilly?
George Budwell, The Motley Fool - Motley Fool - Fri Apr 11, 1:30PM CDT
Many large pharmas in the midst of the so-called "patent cliff" have chosen to turn to their development pipelines for new drugs, instead of playing the merger and acquisition game. This isn't entirely surprising given that valuations for many...
Midday Glance: Pharmaceuticals companies
AP - Fri Apr 11, 12:51PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Pfizer, Visa Weigh on the Dow Even as Banks Grab All the Attention
Dan Caplinger, The Motley Fool - Motley Fool - Fri Apr 11, 11:30AM CDT
It's natural for investors tracking the Dow Jones Industrials to focus on the huge impact that its banking components are having on the average today. With the Dow down 78 points as of 12:30 p.m. EDT, the index's two big investment banks are among...
Dow 30 Stock Roundup: Pfizer Drug Trial Dents, P&G Ups Dividend - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Apr 11, 10:06AM CDT
The Dow experienced an extremely volatile week due to the erratic behavior of momentum stocks.
Watch for Shares of Pfizer (PFE) to Approach Support at $29.93
Comtex SmarTrend(R) - Fri Apr 11, 9:48AM CDT
Pfizer (NYSE
FE) has opened bearishly below the pivot of $30.85 today and has reached the first level of support at $30.27. Investors may be interested in a cross of the next downside pivot targets of $29.93 and $29.01. GCC Select Cardiovascular Drugs Market 2012-16 - Analysis of the $7.6 Billion Industry
M2 - Fri Apr 11, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9g8257/market_for_select) has announced the addition of the "GCC Select Cardiovascular Drugs Market 2012-16 - Analysis of the $7.6 Billion Industry" report to their offering. This report focuses on the market for select cardiovascular drugs in the GCC region. Various market drivers in terms of changing lifestyle and rising disease incidence among the population has led to higher consumption of cardiovascular drugs in the region. Sensing the latent market opportunity, global pharma majors such as Novartis, Abbott, AstraZeneca have set up operations in the GCC region through local joint venture and distribution. The $7.6 bn Pharmaceutical industry in the GCC region is poised for major growth in the coming years. Increase in the international crude oil prices and exports of crude and petro products have transformed the GCC economy. The local governments are increasingly focusing on improving the health and living standards of the population. Contraints in local manufacturing capacity and thriving counterfeit drugs market pose a major challenge but improved regulatory mechanism, increase in private sector participation coupled with rising private and public sector outlay and spend on healthcare presents a promising future for the industry. In addition to market forecast upto 2016, the report also provides interesting insights into key molecules used, top brands, drug prices, procurement process among government and retail institutions. The report will serve as a effective guide for the drug companies, distributors, hospitals and other stakeholders who wish to enter the GCC healthcare market. The report also has profiles of companies and distributors in the GCC region. Key Topics Covered: 1. Methodology 2. Report Coverage 3. Glossary of terms 4. Executive summary 5. Healthcare sector in GCC 6. Pharmaceutical market in GCC 7. Cardiovascular market for select drugs in GCC 8. Profiles of key domestic pharmaceutical manufacturers 9. Annexure - Drugs price details by country - 2012 Companies Mentioned: - AstraZeneca - Global Pharma - Jamjoom Pharma - Julphar - Gulf Pharmaceutical Industries - Kuwait Saudi Pharmaceutical Industries - Merck & Co., Inc - National Pharmaceutical Industries Co - Neo Pharma - Novartis International AG - Oman Pharmaceutical Products Co. L.L.C - Pfizer, Inc - Sanofi S.A. - Saudi Pharmaceutical Industries & Medical Appliances Corporation - Tabuk Pharmaceuticals Manufacturing Company For more information visit http://www.researchandmarkets.com/research/9g...for_select
Priority Reviews, Preliminary Earnings Releases, Clinical Trials Results, and Launch of Website - Analyst Notes on Gilead, Pfizer, Intuitive Surgical, Alkermes and Quest
PR Newswire - Fri Apr 11, 9:14AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Intuitive Surgical, Inc. (NASDAQ: ISRG), Alkermes plc (NASDAQ: ALKS) and Quest Diagnostics Inc. (NYSE: DGX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/989-100free.
Pfizer's Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts
Business Wire - Fri Apr 11, 8:00AM CDT
Ian C. Read, chairman and CEO of Pfizer, Inc, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association's annual meeting. Also elected were Kenneth C. Frazier, chairman, president and CEO of Merck & Co, Inc., as chairman-elect of the PhRMA Board of Directors, and George A. Scangos, Ph.D., CEO of Biogen Idec, as Board treasurer.
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
2 Biotech Stocks to Watch: Merrimack Pharmaceuticals and Sunesis Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Apr 10, 5:30PM CDT
Although 2014 has gotten off to a rocky start for biotechs, a fair number of companies have exploded higher after reporting positive clinical trial data. For example, Endocyte doubled in a day after unveiling positive data for its experimental...
Nektar Presents Pipeline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:10PM CDT
Nektar presented preclinical data on NKTR-102 and NKTR-214 at the AACR.
